Literature DB >> 8913835

Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein.

S Urien1, J Barré, C Morin, A Paccaly, G Montay, J P Tillement.   

Abstract

The binding of docetaxel to human plasma proteins was studied by ultrafiltration at 37 degrees C and pH 7.4. Docetaxel was extensively (> 98%) plasma protein bound. At clinically relevant concentrations (1-5 micrograms/ml), the plasma binding was concentration-independent. Lipoproteins, alpha1-acid glycoprotein and albumin were the main carriers of docetaxel in plasma, and owing to the high interindividual variability of alpha1-acid glycoprotein plasma concentration, particularly in cancer, it was concluded that alpha1-acid glycoprotein should be the main determinant of docetaxel plasma binding variability. Drugs potentially coadministered with docetaxel (cisplatin, dexamethasone, doxorubicin, etoposide, vinblastine) did not modify the plasma binding of docetaxel. In blood, docetaxel was found to be mainly located in the plasma compartment (less than 15% associated to erythrocytes).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8913835     DOI: 10.1007/bf00210785

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  9 in total

1.  The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum.

Authors:  R J HAVEL; H A EDER; J H BRAGDON
Journal:  J Clin Invest       Date:  1955-09       Impact factor: 14.808

2.  The plasma protein binding of basic drugs.

Authors:  P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

3.  Determinants of plasma alpha 1-acid glycoprotein (AAG) concentrations in health.

Authors:  P G Blain; J C Mucklow; M D Rawlins; D F Roberts; P A Routledge; D G Shand
Journal:  Br J Clin Pharmacol       Date:  1985-11       Impact factor: 4.335

4.  Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein.

Authors:  G N Kumar; U K Walle; K N Bhalla; T Walle
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1993-06

Review 5.  The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere).

Authors:  R Pazdur; A P Kudelka; J J Kavanagh; P R Cohen; M N Raber
Journal:  Cancer Treat Rev       Date:  1993-10       Impact factor: 12.111

6.  Role of alpha-1 acid glycoprotein, albumin, and nonesterified fatty acids in serum binding of apazone and warfarin.

Authors:  S Urien; E Albengres; J L Pinquier; J P Tillement
Journal:  Clin Pharmacol Ther       Date:  1986-06       Impact factor: 6.875

7.  Methadone plasma protein binding: alterations in cancer and displacement from alpha 1-acid glycoprotein.

Authors:  F P Abramson
Journal:  Clin Pharmacol Ther       Date:  1982-11       Impact factor: 6.875

8.  Binding of indapamide to serum proteins and erythrocytes.

Authors:  S Urien; P Riant; A Renouard; B Coulomb; I Rocher; J P Tillement
Journal:  Biochem Pharmacol       Date:  1988-08-01       Impact factor: 5.858

Review 9.  Pharmacokinetics and metabolism of Taxotere (docetaxel).

Authors:  R Bruno; G J Sanderink
Journal:  Cancer Surv       Date:  1993
  9 in total
  26 in total

1.  Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.

Authors:  J H M Schellens; B Heinrich; M Lehnert; M E Gore; S B Kaye; P Dombernowsky; R Paridaens; A T van Oosterom; J Verweij; W J Loos; H Calvert; N Pavlidis; H Cortes-Funes; J Wanders; M Roelvink; C Sessa; K Selinger; P S Wissel; T Gamucci; A R Hanauske
Journal:  Invest New Drugs       Date:  2002-02       Impact factor: 3.850

2.  In vitro binding and partitioning of irinotecan (CPT-11) and its metabolite, SN-38, in human blood.

Authors:  O Combes; J Barré; J C Duché; L Vernillet; Y Archimbaud; M P Marietta; J P Tillement; S Urien
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

Review 3.  Docetaxel: a review of its use in non-small cell lung cancer.

Authors:  A M Comer; K L Goa
Journal:  Drugs Aging       Date:  2000-07       Impact factor: 3.923

Review 4.  Docetaxel: an update of its use in advanced breast cancer.

Authors:  D P Figgitt; L R Wiseman
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

5.  Immune activation mediated change in alpha-1-acid glycoprotein: impact on total and free lopinavir plasma exposure.

Authors:  Ighovwerha Ofotokun; Jeffrey L Lennox; Molly E Eaton; James C Ritchie; Kirk A Easley; Svetlana E Masalovich; Mary C Long; Edward P Acosta
Journal:  J Clin Pharmacol       Date:  2011-01-05       Impact factor: 3.126

6.  Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients.

Authors:  Oliver von Richter; Giorgio Massimini; Holger Scheible; Istvan Udvaros; Andreas Johne
Journal:  Br J Clin Pharmacol       Date:  2016-09-19       Impact factor: 4.335

7.  Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer.

Authors:  Islam R Younis; Daniel J George; Terence J McManus; Herbert Hurwitz; Patricia Creel; Andrew J Armstrong; Jing Jie Yu; Kristina Bacon; Gerald Hobbs; Cody J Peer; William P Petros
Journal:  Cancer Chemother Pharmacol       Date:  2014-03-12       Impact factor: 3.333

8.  Incorporation of ABCB1-mediated transport into a physiologically-based pharmacokinetic model of docetaxel in mice.

Authors:  Susan F Hudachek; Daniel L Gustafson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-04-25       Impact factor: 2.745

9.  Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model.

Authors:  Lena E Friberg; Marie Sandström; Mats O Karlsson
Journal:  Invest New Drugs       Date:  2009-08-27       Impact factor: 3.850

10.  Population pharmacokinetics of weekly docetaxel in patients with advanced cancer.

Authors:  Kellie A Slaviero; Stephen J Clarke; Andrew J McLachlan; Elaine Y L Blair; Laurent P Rivory
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.